We'll review your medical background, BMI, and weight loss objectives to identify the medication best suited for you
doi: 10.1007/s10517-006-0365-z
Overall, although the overall absolute risk increase is small (27 cases per 10,000 persons treated per year), clinical practitioners should nevertheless take into account the potential risk of gallbladder or biliary diseases associated with GLP-1RAs, especially when used at higher doses, for longer durations, and for weight loss, and in case the patient has a history of lithiasis [64]
J.AschenbrennerA
In addition to the newer GLP-1 drugs on the market, the study evaluated clinical trials on various weight-loss drugs, including older-generation GLP-1 medications and those outside of the class, such as orlistat and the combination of phentermine and topiramate